Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network - Coordination and Data Sharing Center (CDSC) (UG3/UH3 Clinical Trial Not Allowed) | RFA AI 23 021

Opportunity Information: Apply for RFA AI 23 021

The Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network - Coordination and Data Sharing Center (CDSC) funding opportunity (RFA-AI-23-021) is an NIH cooperative agreement designed to stand up a central hub that keeps the broader ReVAMPP effort organized, connected, and operating as a true network. The CDSC is meant to work hand-in-hand with multiple ReVAMPP Centers; together, the CDSC plus those Centers make up the ReVAMPP Network. The overall aim is pandemic preparedness, specifically by accelerating and coordinating research that supports vaccines and monoclonal antibodies across targeted virus families, while keeping data, tools, and approaches aligned across participating groups. This FOA is explicitly listed as UG3/UH3 and "Clinical Trial Not Allowed," which signals a phased cooperative structure focused on planning/early activities and then implementation, but not on running clinical trials under this particular award.

At its core, the CDSC is expected to function as the operational backbone of the ReVAMPP Network. That includes supporting, coordinating, and managing both ongoing and planned network activities so that the Centers are not working in silos. A major deliverable is a collaborative platform for data sharing that can be used to harmonize and standardize key inputs across the network, such as reagents, assays, and animal models. The CDSC is also expected to make it easier for Centers to exchange knowledge related to structure/function-based vaccine solutions and antigen or immunogen design, which are central themes in modern vaccine R&D. Another important responsibility is helping the network assess and compare the utility of different vaccine technology platforms for the virus families being studied by the ReVAMPP Centers, so that decisions and research directions can be informed by shared evidence rather than isolated experiences.

Beyond technical coordination, the CDSC has a strong communications and project-management mandate. It must facilitate effective communication across all ReVAMPP Centers by scheduling and managing meetings, building routines for regular coordination, and ensuring that information is captured and distributed efficiently. The center is also expected to track overall network progress and outputs, which typically implies establishing shared milestones, reporting structures, and mechanisms to monitor deliverables across sites. In addition, the CDSC should actively create opportunities for collaboration, for example by forming working groups around shared scientific or operational challenges, and by providing administrative and informatics support that helps those working groups produce usable, network-wide outputs.

The FOA also makes clear that the CDSC is not only inward-facing. Under the direction of NIAID, the CDSC is expected to collate information and facilitate exchange with other NIAID/NIH programs, U.S. Government partners, and other key stakeholders. The opportunity specifically names external stakeholders such as the World Health Organization (WHO), the Bill and Melinda Gates Foundation (BMGF), and the Coalition for Epidemic Preparedness Innovations (CEPI), among others as appropriate. In practical terms, this positions the CDSC as a liaison that can translate and share non-confidential network activities, align where possible with related initiatives, and reduce duplication by keeping the ReVAMPP Network connected to the wider pandemic preparedness ecosystem.

From an administrative standpoint, this is a discretionary funding opportunity using a cooperative agreement mechanism, meaning NIH (here, NIAID) is expected to have substantial programmatic involvement rather than acting only as a passive funder. The activity category is Health, and the CFDA number listed is 93.855. The award ceiling shown is $1,500,000. The FOA anticipated awards field is not specified in the provided text. The original closing date was June 8, 2023, and the opportunity was created March 16, 2023.

Eligibility is broad across typical U.S. applicant categories, including state, county, and local governments; special districts; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments; tribal organizations (including those other than federally recognized tribal governments); public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses. The FOA also explicitly calls out additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, faith-based or community-based organizations, Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, U.S. territories or possessions, and eligible federal agencies. At the same time, it draws clear boundaries around foreign involvement: non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply, but foreign components are allowed as defined by the NIH Grants Policy Statement. This distinction generally means a U.S. applicant can include certain foreign collaborations or performance sites if justified and compliant, but the applying organization itself must be domestic and cannot be a non-U.S. institution.

Overall, the opportunity is best understood as funding the shared infrastructure and coordination function for a multi-center pandemic preparedness network: building the systems for data and resource sharing, aligning methods and models, organizing working relationships, tracking network productivity, and serving as an NIAID-directed connector to other major public and global health stakeholders. The scientific advances produced by the ReVAMPP Centers are intended to move faster and be more comparable and reusable precisely because the CDSC keeps the network synchronized on platforms, standards, and communication.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network - Coordination and Data Sharing Center (CDSC) (UG3/UH3 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
• This funding opportunity was created on 2023-03-16.
• Applicants must submit their applications by 2023-06-08. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $1,500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA AI 23 021

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: